<DOC>
	<DOC>NCT01089751</DOC>
	<brief_summary>This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.</brief_summary>
	<brief_title>Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Taking DetrolÂ® LA 4mg daily for a minimum of 1 month prior to Screening/Qualification Overactive Bladder syndrome with urgency, urinary frequency and urgency urinary incontinence Taking five or more concomitant medications (may be prescription, nonprescription, or supplement/vitamin) daily for indications other than Overactive Bladder (OAB). Predominant stress or insensate incontinence History of neurogenic bladder Two urinary tract infections in the last six months Gastric bypass (RouxenY) surgery (adjustable gastric banding is allowed) Donated &gt;500mL blood in the 30 days prior to the screening visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>